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Abstract 
HMGA2, the High Mobility Group A2 gene, is a 
non-histone and architectural transcription factor. As 
an oncofetal protein, HMGA2 plays an important 
role in development and contributes to the 
tumorigenesis of many epithelial and mesenchymal 
tumors.  
Upregulation of HMGA2 by non-random 
chromosomal translocations is common in 
mesenchymal tumors, whereas by the altered 
transcription regulation is likely the major 
mechanism in malignant epithelial tumors and it 
involves much more complex mechanisms. HMGA2 
directly and indirectly regulates the multiple 
biological and oncogenic pathways. Its oncogenic 
property remains to be fully characterized. 
Keywords 
HMGA2, Development, miRNA regulation, Stem 
cell self-renewal, transcription regulation, Oncofetal 
protein, neoplasia, Aging and senescence, epithelial-
to-mesenchymal transition (EMT), non-random 
chromosomal translocation. 
Identity 
Other names: HMGIC, BABL, LIPO, STQTL9 
HGNC (Hugo): HMGA2 
Location: 12q14.3 
Local order 
telomeric to CDK4, centromeric to MDM2 
FISH Probe(s) - Courtesy Mariano Rocchi 
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HMGA2 has long UTR (about 3,000 nt). HMGA2 can be potentially regulated by multiple miRNAs and one of well characterized 
miRNAs is let-7 family which contains at least five predicted bindings sites. MIRLET7E (Let-7) repression of HMGA2 expression 
at transcription and translation has been demonstrated in several different studies (Lee and Dutta 2007, Wang et al. 2007, Peng 
et al. 2008). Inverse association of Let-7 and HMGA2 is an important regulation mechanism in normal development and 
abnormal tumorigensis (Park et al. 2007, Shell et al. 2007). 
 
DNA/RNA 
Description 
5 exons, spans approximately 160 kb; a sixth 
alternative terminal exon within intron 3 has been 
described 
Transcription 
RNA: 4.1 kb.  
Transcription initiated from two different promoter 
regions. A polymorphic dinucleotide repeat 
upstream of the ATG start codon strongly regulates 
HMGA2 expression. Moreover, HMGA2 is 
controlled by negatively acting regulatory elements 
within the 3'UTR 
Protein 
 
 
Description 
109 amino acids; three DNA binding domains (AT  
hooks) linked to the carboxy-terminal acidic domain 
that does not activate transcription. 
 
HMGA2 can directly regulate expression of many genes. 
Specific recognition of AT-rich DNA sequences by HMGA2 
was reporte by a SELEX study. The relative heights are 
proportional to their frequencies shown in the 71 SELEX 
sequences (Cui and Leng 2007). 
Expression 
Fetal tissues: expression in various tissues, 
prominent in kidney, liver and uterus; adult tissues: 
no expression except in lung and kidney; tumors: 
expression in benign mesenchymal tumor tissues 
correlated to 12q15 rearrangements; expressed in 
malignant tumours (e.g., in breast tumours, pancreas 
tumours, ovarian cancer, lung tumours, colorectal 
cancer, nerve system tumours, oral cavity squamous 
cell cancer). 
Localisation 
Nuclear 
 
Inverse expression pattern of HMGA2 and let-7 family in developmental and adulthood stages as well as neoplastic change 
(Park, Shell et al. 2007). 
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Immunohistochemistry shows that HMGA2 is specifically expressed and located in nucleus. Photomicrographs illustrate strong 
immunoreactivity for HMGA2 in leiomyoma with t(12;14) translocation and high grade serous ovarian carcinoma (Wu and Wei 
2013, Bertsch et al. 2014). 
 
 
It is widely accepted that functional CDKN2A (p16INK4a) and RB1 (pRb) as well as the HMGA2, which accumulate at E2F target 
promoters during senescence, are critically required for SAHF arrangement (Narita et al. 2006). 
 
 
HMGA2 is regulated by non-coding miRNAs and coding genes. As a non-histone nuclear transcription regulator, HMGA2 has a 
broad influence in many gene expression, mainly target at epithelial-to-mesenchymal transition (EMT), cell proliferation, DNA 
damage repair, stem cell self-renewal and differentiation, as well as tumorigenesis of many benign and malignant mesenchymal 
and epithelial tumors (Wu and Wei 2013). 
 
 
HMGA2 regulates stem cell potential for self-renewal. HMGA2 seems to be a major regulator of INK4a/ARF expression. HMGA2 
reduces INK4A and ARF expression. HMGA2 binds to the Junb locus. As JUNB promotes INK4A/ARF expression in stem cells, 
thus promoting stem cell self-renewal. Increase in let-7 expression results in the downregulation of HMGA2 and the derepression 
of the INK4a/ARF and activation of p16INK4a expression in self-renewing cells. In Hmga2-deficient mice, it shows reduced stem 
cell numbers and self-renewal. Furthermore, p16(Ink4a) and p19(Arf) expression were increased in Hmga2-deficient fetal and 
young-adult stem cells, and deletion of p16(Ink4a) and/or p19(Arf) partially restored self-renewal capacity. (Yu et al. 2007, 
Nishino et al. 2008). 
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Function 
Architectural factor, non histone, preferential 
binding to AT rich sequences in the minor groove of 
DNA helix; the precise function remains to be 
elucidated; probable role in regulation of cell 
proliferation. 
Homology 
Member of the HMGI protein family. 
Mutations 
Germinal 
Deletion of HMGIC in mutant mice or transgenic 
'knock out' mice for the first two exons of HMGIC 
have the "pigmy" phenotype: low birth weight, 
craniofacial defects, adipocyte hypoplasia adult 
body weight about 40% of normal; mice with a 
partial or complete deficiency of HMGA2 resisted 
diet-induced obesity implicating a role of the gene in 
fat cell proliferation; truncations of mouse Hmga2 in 
transgenic mice result in somatic overgrowth and, in 
particular, increased abundance of fat and lipomas; 
overexpression of the HMGA2 gene in transgenic 
mice leads to the onset of pituary adenomas secreting 
prolactic and growth hormone; HMGA2-null mice 
had very few spermatids and complete absence of 
spermatozoa. 
8-year-old boy had a de novo pericentric inversion 
of chromosome 12, with breakpoints at p11.22 and 
q14.3.  
The phenotype included extreme somatic 
overgrowth, advanced endochondral bone and dental 
ages, a cerebellar tumour, and multiple lipomas. His 
chromosomal inversion was found to truncate 
HMGA2, which maps to the 12q14.3 breakpoint. 
Implicated in 
MESENCHYMAL BENIGN TUMORS 
as follows: 
Lipoma 
Disease 
benign adipocyte tumor 
Prognosis 
good 
Cytogenetics 
various rearrangements involving 12q15 
(translocations, inversions, deletions...); reciprocal 
translocations involve 12q15 with different partners 
such as chromosomes 1, 2, 3, 7, 10, 11, 13, 15, 17, 
21, X; the most frequent anomaly is t(3;12)(q27-
28;q15); cryptic rearrangements, such as paracentric 
inversions not detectable by conventional 
cytogenetics but detectable by FISH, have been 
described. 
Hybrid/Mutated gene 
for t(3;12): HMGIC-LPP (LPP: lipoma preferred 
partner; 3q27-28); a gene located in 13q, LHFP 
(lipoma HMGIC fusion partner) was found to be 
fused with HMGIC in one case of lipoma; one 
lipoma displayed fusion of HMGA2 exon 4 with a 
sequence from intron 4, indicating abnormal 
splicing; HMGA2-CMKOR1 in three cases with 
aberrations involving 2q35-37 and 12q13-15; 
HMGA2-NFIB in one lipoma; 
Abnormal protein 
HMGIC-LPP; the three AT hook domains at the 
aminoterminal of HMGIC are fused to the LIM 
domain of LPP; another fusion protein due to the 
fusion of HMGIC with a putative gene located at 
15q24 predicted to encode a protein with a 
serine/threonine-rich domain has also been 
described 
Oncogenesis 
the relevance of the exact role LPP in the HMGA2-
LPP fusion is not established yet, but the 
transactivation functions of the LPP LIM domains is 
retained in the fusion protein and the fusion protein 
can function as a transcription factor; the truncation 
of HMGA2 by itself may have a role in the 
tumorigenesis 
Uterine leiomyoma (uterine fibroids) 
Disease 
benign mesenchymal tumors 
Prognosis 
good 
Cytogenetics 
approximately 40% of uterine leiomyomas have 
structural chromosomal rearrangements, about 10% 
of which involve 12q15 (translocations, inversions, 
deletions...); the most frequent anomaly is 
t(12;14)(q15;q23-24) 
Hybrid/Mutated gene 
in a majority of cases, there is no fusion gene: the 
breakpoint is located 10 kb up to 100 kb 5' to 
HMGIC; the recombinational repair gene RAD51B 
is a candidate to be the partner gene of HMGIC in 
t(12;14). In two cases (out of 81 primary tumors) 
exon 7 of RAD51B was fused in frame to either exon 
2 or 3 of the HMGA2 gene; in one case with 
paracentric inversion, HMGIC exon 3 was fused to 
ALDH2 exon 13 (12q24.1); in one case (no 
cytogenetic analysis) HMGIC exon 3 was fused to 
COX6C 3' UTR (8q22-23); in one case, with 
apparently normal karyotype, exon 3 of HMGIC was 
fused to retrotransposon-like sequences RTVLH 3' 
LTRs; three fusion transcripts contained 3' cryptic 
exonic sequences present in intron 3 of the HMGA2 
gene (breakpoints downstream of exons 3 or 4), 
suggesting that they are due to alternative splicing; 
one case displayed fusion of the first two exons of 
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HMGA2 to the 3' portion of the 
CCNB1IP1/C14orf18/HEI10 gene 
 
Abnormal protein 
HMGIC-ALDH2: ALDH2 contribution was only 10 
amino acids; 
Oncogenesis 
HMGIC-ALDH2: it is suggested that the truncation 
of HMGIC, rather than fusion may be responsible for 
tumorigenesis; the 3' untranslated region may 
stabilize the HMGIC messenger RNA 
Pleomorphic adenoma of the salivary 
gland (or mixed salivary gland tumor) 
Disease 
benign tumors from the major or minor salivary 
glands 
Prognosis 
good 
Cytogenetics 
approximately 12% of pleomorphic adenomas of 
salivary glands show abnormalities involving 
HMGIC in 12q15; the most frequent aberration is 
t(9;12)(p24.1;q15) 
Hybrid/Mutated gene 
in t(9;12): HMGIC-NFIB fusion; another type of 
fusion HMGIC-FHIT (3p14.2) has also been 
described 
Pulmonary chondroid hamartoma of 
the lung 
Disease 
benign mesenchymal tumors of the lung 
Prognosis 
good 
Cytogenetics 
various rearrangements involving 12q15 leading to 
HMGIC dysregulation; cryptic rearrangements such 
as paracentric inversions not detectable by  
 
 
 
conventional cytogenetics but detectable by FISH 
have been described. 
Hybrid/Mutated gene 
in two cases with apparently normal karyotypes, 
exon 3 of HMGIC was fused to retrotransposon-
like sequences RTVLH 3' LTRs; in cases with 
t(3;12)(q27-28;q14-15) (see lipomas), a fusion of 
HMGA2-LPP was described; only 1/61 cases with 
normal karyotype displayed HMGA2-LPP fusion; 
three cases with rearrangements involving 12q14-
15 and 13q12-14 lacked rearrangements of 
HMGA2-LHFP  
Endometrial polyps 
Disease 
uterine benign tumors 
Prognosis 
good 
Cytogenetics 
various rearrangements involving 12q15 leading to 
HMGIC dysregulation; cryptic rearrangements such 
as paracentric inversions not detectable by 
conventional cytogenetics but detectable by FISH 
have been described; in one case, HMGIC was 
amplified and overexpressed 
Myofibroblastic inflammatory tumor 
Disease 
benign mesenchymal tumors 
Prognosis 
good 
Cytogenetics 
in one case, a complex rearrangement involving 
chromosomes 12 (in 12q15), 4 and 21 was described 
Hybrid/Mutated gene 
an aberrant transcript was produced by the fusion of 
HMGIC exon 3 to an ectopic sequence originating 
from the third intron of HMGIC 
Chondrolipoangioma 
Disease 
a rare benign type of mesenchyomas composed 
predominantly of cartilage and adipose tissue with 
vascular elements and myxoid elements 
 
 
HMGA2 and MED12 mutations are mutually exclusive and are the two independent factors for tumorigenesis of leiomyoma 
(Bertsch et al. 2014). 
Cytogenetics 
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One case demonstrated t(12;15)(q13;q26). FISH 
analysis revealed rearrangement of chromosomes 2, 
12 and 15 and HMGA2. 
Chondromas 
Disease 
benign cartilage tumours 
Cytogenetics 
HMGA2 was expressed in 4/6 soft tissue 
chondromas (all with 12q-rearrangements 
cytogenetically), three cases showed truncated 
(exons 1-3) transcripts, one case displayed a 
t(3;12)(q27;q15) and RT-PCR demonstrated a 
HMGA2-LPP fusion transcript composed of 
HMGA2 exons 1-3 and LPP exons 9-11. 
Hyaline vascular Castleman's 
disease 
Cytogenetics 
one case with der(6)t(6;12)(q23;q15)del(12)(q15) is 
described. 
Hybrid/Mutated gene 
a combined immunologic-cytogenetic approach 
demonstrated HMGA2 rearrangement in follicular 
dendritic cells 
Prolactinoma 
Disease 
prolactin-secreting pituary adenoma, non-
metastasizing 
Cytogenetics 
trisomy 12 nonrandom finding in pituary adenomas 
Hybrid/Mutated gene 
HMGA2 locus amplified in 7/8 prolactinomas 
Aggressive angiomyxoma of the 
vulva 
Disease 
myxoid mesenchymal neoplasm 
Prognosis 
infiltrative neoplasm, locally destructive 
recurrences, no metastatic potential 
Cytogenetics 
one case displayed t(8;12)(p12;q15) 
Hybrid/Mutated gene 
FISH demonstrated a breakpoint 3' of the gene, the 
tumour expressed HMGA2 
MALIGNANT TUMORS as follows: 
Well-differentiated liposarcoma 
Disease 
malignant adipocyte tumor; peripheral or 
retroperitoneal location 
 
 
Prognosis 
rather good; borderline malignancy; locally 
aggressive, rarely metastasizes 
Cytogenetics 
supernumerary ring or giant marker chromosomes 
containing 12q14-15 amplification (surrounding 
MDM2); HMGIC is frequently amplified together 
with MDM2; rearrangement of HMGA2, in addition 
to amplification has been described 
Hybrid/Mutated gene 
ectopic sequences from 12q14-15, 1q24, 11q14, and 
chromosome 2 was shown to be fused to HMGA2 
exon 2 or 3 
Uterine leiomyosarcoma 
Disease 
malignant counterpart of uterine leiomyoma 
Prognosis 
poor 
Cytogenetics 
12q13-15 region is recurrently amplified 
Hybrid/Mutated gene 
HMGA2 amplified within this region 
Osteosarcoma 
Disease 
malignant tumor 
Hybrid/Mutated gene 
in one osteosarcoma cell line (OsA-Cl) the three 
DNA binding domains of HMGIC fused to the 
keratan sulfate protein glycan gene LUM (12q22-
23); LUM was fused out of frame, and only 3 amino 
acids were fused to HMGIC; in addition, the 
rearranged gene was amplified 
Myelofibrosis with myeloid 
metaplasia 
Disease 
rare chronic myeloproliferative disorder 
Prognosis 
variable 
Cytogenetics 
one case with t(4;12)(q32;q15) and one case with 
t(5;12)(p14;q15) 
Hybrid/Mutated gene 
FISH analysis suggested breakpoint in HMGA2, 
RT-PCR revealed that HMGA2 is expressed in 
blood mononuclear cells from patients with this 
disease 
Acute lymphoblastic leukaemia 
Disease 
Heterogenous disease that arises in precursor B or T 
cells 
 
 
Cytogenetics 
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One case with a t(9;12)(p22;q14), frequent deletions 
at 12q14.3 
Hybrid/Mutated gene 
t(9;12): FISH analysis indicated a breakpoint in the 
5' region of the gene, RT-PCR showed 
overexpression of HMGA2 lacking the 
carboxyterminal tail; deletions covering the 5' end of 
HMGA2 
High-grade serous carcinoma of the 
fallopian tubes 
Disease 
Serous carcinoma arising from fallopian tube 
secretory epithelia. 
Oncogenesis 
Overexpression of HMGA2 regulated by several 
genetic mechanism, including CTNNB1 (β -
Catenin), TGF- β, miRNAs. Currently well definied 
miRNAs including let-7 and MIR-182.  
MiR-182 promotes HMGA2 expression through 
negative regulation of BRCA1 (Moskwa et al. 2011, 
Liu et al. 2012).  
HMGA2 regulates several EMT genes including 
STC2 and LUM (Wu et al. 2011).  
Overexpression of HMGA2 is associated with early 
tumorigenesis, tumor cell proliferation, invasion and 
worse outcome through regulation of cell cycle, 
epithelial to mesenchymal transition (Wu et al. 
2011). 
Pancreatic carcinoma 
Disease 
Pancreatic ductal carcinoma. 
Oncogenesis 
Overexpression of HMGA2 promote EMT by 
regulation of SNAIL, SLUG, SIP1, TCF3 
(E12/E47), and ZEB1 (Watanabe et al. 2009).  
HMGA2 nuclear immunoreactivity correlates 
positively with lymph node metastases and high 
tumor grade (Hristov et al. 2009). 
Breast Cancer 
Disease 
Serous carcinoma arising from fallopian tube 
secretory epithelia. 
Oncogenesis 
HMGA2 gene and protein are highly expressed in 
metastatic breast cancer cells. HMGA2 as an 
important regulator of PAR1-mediated invasion.  
Inhibition of PAR1 signaling suppresses HMGA2-
driven invasion in breast cancer cells (Yang et al. 
2015). 
Colon Cancer 
Disease 
Colonic adenocarcinoma. 
Oncogenesis 
HMGA2 delays the clearance of H2AFX(γ-H2AX) 
in colon cancer.   
Overexpression of HMGA2 is associated with 
metastasis and unequivocally occurred in parallel 
with reduced survival rates of patients with 
colorectal carcinoma (Wang et al. 2011). 
Lung Cancer 
Disease 
Non-small-cell lung cancer (NSCLC) 
Oncogenesis 
HMGA2 can operate as competing endogenous 
RNA (ceRNA) for the let-7 microRNA (miRNA) 
family, suggesting that Hmga2 affects let-7 activity 
by altering miRNA targeting.  
HMGA2 promotes the transformation of lung cancer 
cells independent of protein-coding function. Tgfbr3 
expression is regulated by the Hmga2 ceRNA 
through differential recruitment to Argonaute 2 
(AGO2), and TGF-β signalling driven by Tgfbr3 is 
important for Hmga2 to promote lung cancer 
progression (Kumar et al. 2014). 
Breakpoints 
See below. 
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Up to 21 partners have a breakpoint with HMGA2 are summarized. The majority of this non-random translocations were found to 
be in mesenchymal neoplasia (Wu and Wei 2013). 
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